The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A whole transcriptome sequencing (WTS)-based cMet dysregulation biomarker assay with correlates to cMet DNA mutations and cMet protein expression.
 
Xiaoling Zhang
Employment - Apollomics; AstraZeneca
Stock and Other Ownership Interests - Agios; Apollomics; Bristol-Myers Squibb; Clovis Oncology; Dynavax Technologies; Exelixis; Fate Therapeutics; FibroGen; ImmunoGen; Immunomedics; Karyopharm Therapeutics
Patents, Royalties, Other Intellectual Property - PCT/CN2019/092706; PCT/CN2019/109906
 
Phillip Stafford
Employment - Caris Life Sciences
Stock and Other Ownership Interests - Caris Life Sciences
 
Brian Baker
Employment - Caris Life Sciences; Roche
Stock and Other Ownership Interests - Caris Life Sciences; Roche
 
Jeffery Kimbrough
Employment - Caris Life Sciences
 
Fabio M. Benedetti
Employment - Apollomics; Taiho Oncology
Leadership - Apollomics; Taiho Pharmaceutical
Stock and Other Ownership Interests - Abbvie; Acadia; Affimed Therapeutics; Aimmune; Alnylam; Amarin Corporation; Amgen; Apollomics; ArQule; Array BioPharma; Asterias Biotherapeutics; AstraZeneca; Atara Biotherapeutics; Bellicum Pharmaceuticals; Bluebird Bio; Blueprint Medicines; Bristol-Myers Squibb; Cascadian Therapeutics; catabasis; celgene; Cellectis; celyad; crispr therapeutics; Editas Medicine; epizyme; Exelixis; Fate Therapeutics; Forty Seven; Geron; Gilead Sciences; Ignyta; Immunogen; Immunomedics; incyte; Infinity Pharmaceuticals; Intellia Therapeutics; ION Pharma; Johnson & Johnson; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead company; Lexicon; Lilly; loxo; Macrogenics; Medtronic; MEI Pharma; Merck; Neurocrine Biosciences; Newlink Genetics; pfizer; Puma Biotechnology; Regenxbio; Seagen; Spring Bank; Stemline Therapeutics; Syndax; tocagen; Ultragenyx Pharmaceuticals; uniqure; verastem
Patents, Royalties, Other Intellectual Property - 2 patent applications under same Title: Method for treating cancer patients with c-Met point mutation or c-Met fusion gene; 2 patent applications under same Title: Method for treating cancer patients with c-Met point mutation or c-Met fusion gene; A patent relating to telomere length as a predictor for thrombocytopenia for patients treated with GRN163L (a Geron experimental therapeutic)